| Prev Close | 144.67 |
| Day Low/High | 143.89 / 146.25 |
| 52 Wk Low/High | 109.16 / 157.00 |
Johnson & Johnson (JNJ)
145.66
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2632.82B |
| Market Cap | 380.89B |
| P/E Ratio | 25.43 |
| Div & Yield | N.A. (N.A) |
Takeaways and Observations
Let me teach you how to Dougie. Consumer confidence is a coincident/lagging indicator. And excitement over the print, is (quite frankly) "first level thinking." As support, check out these two charts of the day -- it's "second level thinking." Snap ...
More Companies Pull Advertising to Protest Google's Treatment of Extremist Content
Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.
These 3 Would Look Great at Lower Prices
If opportunity knocks, I'm buying.
Health Care Companies Could Be Active Today as Congress Votes
The GOP is scrambling for votes on Obamacare Repeal.
Takeaways & Observations
"I had nothing to offer anybody except my own confusion." -- Jack Kerouac So, color me confused. But I will persevere and write "Takeaways!" While a lot didn't make sense, I suspect many traders/investors were caught "offsides." Peter Boockvar do...
Health Care Putting in a Base
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Cramer: Top 10 Bull Markets Right Now
Bull market number one, perhaps of all time: the financials.
Tech Stocks Under Trump
They might have an issue with corporate tax reform.
Cramer: This Drug Rally Is No Longer 'Trumped Up'
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
Cramer: When Someone Calls a Market Top, What's Their Motivation?
It's better to be early than wrong. Though being wrong isn't so awful.
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Icahn may have a tough time finding interest in this behemoth.
Takeaways and Observations
Every single market indicator I look at is overbought. But it's likely that shorts and underperformers are buoying stocks. Some are at the most overbought in decades. The bond market is clearly not as sanguine on economic growth/corporate profi...
Health Care ETF Has Been Ailing
You might want to review your holdings in the sector.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion
Integra hopes this deal will grow its revenue to $2 billion sooner than expected.
Cramer: Why Are People Dumping Such Good Stocks?
Amazon, J&J, IBM and others don't deserve this treatment.
Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today
They have become a referendum on Trump's plans for lower corporate taxes.
7 Things to Watch in Biotech Now
M&A, drug approvals and Trump are all on my watch list.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
The Next Target in Biotech Land
The Actelion buyout opens the way for other deals.
My Takeaways and Observations
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
Jim Cramer: Johnson & Johnson Will Do Well With Actelion
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
News Out of Europe: Johnson & Johnson Buys Actelion
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Johnson & Johnson Buys Actelion for $30 Billion
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
Johnson & Johnson Still Too Pricey
The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.
Rev's Forum: Sometimes a Breakout is Just a Breakout
Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.
Global Stocks Are Following Wall Street Higher as Dow Hits 20,000
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
Will Johnson & Johnson's Upside Reversal Last?
I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.
